Odyssey Therapeutics, Inc.

ODTX Nasdaq SEC CIK 1882782
Follow Odyssey Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$53.1M −49.6% vs same quarter last year
EPS, diluted −$1.10 +85.9% vs same quarter last year
Operating cash flow −$41.5M −32.9% vs same quarter last year
Revenue by quarter
$1.9M
$959K
$99K
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing